Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis

Results From a Tight-Control Clinical Trial and an Observational Cohort

Laura C. Coates, William Tillett, Gavin Shaddick, Theodore Pincus, Arthur Kavanaugh, Philip S. Helliwell

Research output: Contribution to journalArticle

4 Citations (Scopus)
27 Downloads (Pure)

Abstract

Objective: To analyze the Routine Assessment of Patient Index Data 3 (RAPID3), a patient-reported, composite index, designed initially for feasibility in clinical care. RAPID3 was developed in rheumatoid arthritis, but has been found useful in many rheumatic diseases. We analyzed RAPID3 in patients with psoriatic arthritis (PsA). Methods: Post hoc analyses were performed on 2 independent data sets, the Tight Control of Psoriatic Arthritis (TICOPA) clinical trial, and the Long-Term Outcome in Psoriatic Arthritis Study (LOPAS II), an observational cohort. RAPID3 (range 0–30) is the total of three 0–10 scores for the Health Assessment Questionnaire disability index (recalculated from 0–3), pain visual analog scale (VAS), and global VAS. RAPID3 scores were compared to the Psoriatic Arthritis Disease Activity Score (PASDAS), the Disease Activity in Psoriatic Arthritis (DAPSA), and other available clinical measures, according to Spearman's correlation coefficients, standardized response mean, SEM, smallest detectible difference, minimally important difference (in patients who improved), and receiver operating characteristic curves. RAPID3 remission was compared to criteria for both standard minimal disease activity (MDA) and very low disease activity (VLDA). Results: RAPID3 was correlated significantly with PASDAS in TICOPA (r = 0.79, P < 0.01) and with DAPSA in LOPAS II (ρ = 0.59, P < 0.01), and with most other measures in both data sets. RAPID3 discriminated between tight control and standard care in TICOPA at 48 weeks at levels comparable to DAPSA and the PASDAS (P < 0.01). RAPID3 remission discriminated treatment groups in TICOPA intermediate between MDA and VLDA criteria. Conclusion: RAPID3 appears comparably informative to PASDAS and DAPSA in PsA, with greater feasibility for routine clinical care.

Original languageEnglish
Pages (from-to)1198-1205
Number of pages8
JournalArthritis Care and Research
Volume70
Issue number8
Early online date7 Nov 2017
DOIs
Publication statusPublished - 1 Aug 2018

Fingerprint

Psoriatic Arthritis
Clinical Trials
Pain Measurement
Rheumatic Diseases
Visual Analog Scale
ROC Curve

Keywords

  • Journal Article

ASJC Scopus subject areas

  • Rheumatology

Cite this

Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis : Results From a Tight-Control Clinical Trial and an Observational Cohort. / Coates, Laura C.; Tillett, William; Shaddick, Gavin; Pincus, Theodore; Kavanaugh, Arthur; Helliwell, Philip S.

In: Arthritis Care and Research, Vol. 70, No. 8, 01.08.2018, p. 1198-1205.

Research output: Contribution to journalArticle

@article{3cab52adfd66404f90743a2683cae2ca,
title = "Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort",
abstract = "Objective: To analyze the Routine Assessment of Patient Index Data 3 (RAPID3), a patient-reported, composite index, designed initially for feasibility in clinical care. RAPID3 was developed in rheumatoid arthritis, but has been found useful in many rheumatic diseases. We analyzed RAPID3 in patients with psoriatic arthritis (PsA). Methods: Post hoc analyses were performed on 2 independent data sets, the Tight Control of Psoriatic Arthritis (TICOPA) clinical trial, and the Long-Term Outcome in Psoriatic Arthritis Study (LOPAS II), an observational cohort. RAPID3 (range 0–30) is the total of three 0–10 scores for the Health Assessment Questionnaire disability index (recalculated from 0–3), pain visual analog scale (VAS), and global VAS. RAPID3 scores were compared to the Psoriatic Arthritis Disease Activity Score (PASDAS), the Disease Activity in Psoriatic Arthritis (DAPSA), and other available clinical measures, according to Spearman's correlation coefficients, standardized response mean, SEM, smallest detectible difference, minimally important difference (in patients who improved), and receiver operating characteristic curves. RAPID3 remission was compared to criteria for both standard minimal disease activity (MDA) and very low disease activity (VLDA). Results: RAPID3 was correlated significantly with PASDAS in TICOPA (r = 0.79, P < 0.01) and with DAPSA in LOPAS II (ρ = 0.59, P < 0.01), and with most other measures in both data sets. RAPID3 discriminated between tight control and standard care in TICOPA at 48 weeks at levels comparable to DAPSA and the PASDAS (P < 0.01). RAPID3 remission discriminated treatment groups in TICOPA intermediate between MDA and VLDA criteria. Conclusion: RAPID3 appears comparably informative to PASDAS and DAPSA in PsA, with greater feasibility for routine clinical care.",
keywords = "Journal Article",
author = "Coates, {Laura C.} and William Tillett and Gavin Shaddick and Theodore Pincus and Arthur Kavanaugh and Helliwell, {Philip S.}",
note = "{\circledC} 2017, American College of Rheumatology.",
year = "2018",
month = "8",
day = "1",
doi = "10.1002/acr.23460",
language = "English",
volume = "70",
pages = "1198--1205",
journal = "Arthritis Care and Research",
issn = "2151-464X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis

T2 - Results From a Tight-Control Clinical Trial and an Observational Cohort

AU - Coates, Laura C.

AU - Tillett, William

AU - Shaddick, Gavin

AU - Pincus, Theodore

AU - Kavanaugh, Arthur

AU - Helliwell, Philip S.

N1 - © 2017, American College of Rheumatology.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Objective: To analyze the Routine Assessment of Patient Index Data 3 (RAPID3), a patient-reported, composite index, designed initially for feasibility in clinical care. RAPID3 was developed in rheumatoid arthritis, but has been found useful in many rheumatic diseases. We analyzed RAPID3 in patients with psoriatic arthritis (PsA). Methods: Post hoc analyses were performed on 2 independent data sets, the Tight Control of Psoriatic Arthritis (TICOPA) clinical trial, and the Long-Term Outcome in Psoriatic Arthritis Study (LOPAS II), an observational cohort. RAPID3 (range 0–30) is the total of three 0–10 scores for the Health Assessment Questionnaire disability index (recalculated from 0–3), pain visual analog scale (VAS), and global VAS. RAPID3 scores were compared to the Psoriatic Arthritis Disease Activity Score (PASDAS), the Disease Activity in Psoriatic Arthritis (DAPSA), and other available clinical measures, according to Spearman's correlation coefficients, standardized response mean, SEM, smallest detectible difference, minimally important difference (in patients who improved), and receiver operating characteristic curves. RAPID3 remission was compared to criteria for both standard minimal disease activity (MDA) and very low disease activity (VLDA). Results: RAPID3 was correlated significantly with PASDAS in TICOPA (r = 0.79, P < 0.01) and with DAPSA in LOPAS II (ρ = 0.59, P < 0.01), and with most other measures in both data sets. RAPID3 discriminated between tight control and standard care in TICOPA at 48 weeks at levels comparable to DAPSA and the PASDAS (P < 0.01). RAPID3 remission discriminated treatment groups in TICOPA intermediate between MDA and VLDA criteria. Conclusion: RAPID3 appears comparably informative to PASDAS and DAPSA in PsA, with greater feasibility for routine clinical care.

AB - Objective: To analyze the Routine Assessment of Patient Index Data 3 (RAPID3), a patient-reported, composite index, designed initially for feasibility in clinical care. RAPID3 was developed in rheumatoid arthritis, but has been found useful in many rheumatic diseases. We analyzed RAPID3 in patients with psoriatic arthritis (PsA). Methods: Post hoc analyses were performed on 2 independent data sets, the Tight Control of Psoriatic Arthritis (TICOPA) clinical trial, and the Long-Term Outcome in Psoriatic Arthritis Study (LOPAS II), an observational cohort. RAPID3 (range 0–30) is the total of three 0–10 scores for the Health Assessment Questionnaire disability index (recalculated from 0–3), pain visual analog scale (VAS), and global VAS. RAPID3 scores were compared to the Psoriatic Arthritis Disease Activity Score (PASDAS), the Disease Activity in Psoriatic Arthritis (DAPSA), and other available clinical measures, according to Spearman's correlation coefficients, standardized response mean, SEM, smallest detectible difference, minimally important difference (in patients who improved), and receiver operating characteristic curves. RAPID3 remission was compared to criteria for both standard minimal disease activity (MDA) and very low disease activity (VLDA). Results: RAPID3 was correlated significantly with PASDAS in TICOPA (r = 0.79, P < 0.01) and with DAPSA in LOPAS II (ρ = 0.59, P < 0.01), and with most other measures in both data sets. RAPID3 discriminated between tight control and standard care in TICOPA at 48 weeks at levels comparable to DAPSA and the PASDAS (P < 0.01). RAPID3 remission discriminated treatment groups in TICOPA intermediate between MDA and VLDA criteria. Conclusion: RAPID3 appears comparably informative to PASDAS and DAPSA in PsA, with greater feasibility for routine clinical care.

KW - Journal Article

UR - http://www.scopus.com/inward/record.url?scp=85050637034&partnerID=8YFLogxK

U2 - 10.1002/acr.23460

DO - 10.1002/acr.23460

M3 - Article

VL - 70

SP - 1198

EP - 1205

JO - Arthritis Care and Research

JF - Arthritis Care and Research

SN - 2151-464X

IS - 8

ER -